{
    "nct_id": "NCT03822871",
    "official_title": "A Phase 1 Trial for Evaluation of Safety and 177Lu Radiation Dosimetry of CTT1403: A Peptidomimetic Inhibitor of Prostate Specific Membrane Antigen, in Metastatic Castration Resistant Prostate Cancer (mCRPC)",
    "inclusion_criteria": "* Patients must have histologically confirmed prostate adenocarcinoma that is metastatic and castration resistant (mCRPC).\n* At least 3 metastatic foci avid for PSMA-specific PET agent (CTT1057) uptake on Screening PSMA PET.\n* Has received docetaxol, ineligible for docetaxol, or refused docetaxol for the treatment of prostate cancer.\n* Has progression by the PCWG3 criteria during or after treatment with either abiraterone or enzalutamide\n* Male Age â‰¥ 18 years.\n* Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (see Appendix 2).\n* Demonstrate adequate organ function\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has received previous treatment with radium-223 or another radiopharmaceutical within 3 months prior to first dose of CTT1403.\n* Has received prior systemic anti-cancer therapy (excluding radiopharmaceutical) within 14 days, or 5 half-lives, whichever is shorter, prior to first dose of CTT1403.\n* Has received external-beam radiation within 14 days prior to first dose of CTT1403.\n* Has received cabazitaxel for the treatment of mCRPC.\n* Has received previous treatment with a therapeutic targeting PSMA.\n* Has an additional active malignancy requiring therapy that may confound the assessment of the study endpoints.\n* Has clinically significant cardiovascular disease\n* Has a history of untreated brain metastases\n* Has evidence of diffuse bone marrow involvement by prostate cancer in the judgment of study investigator.\n* Clinically significant urinary obstruction or moderate/severe hydronephrosis on baseline imaging.\n* Has a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days before CTT1403 administration.\n* Has known positive status for chronic hepatitis B or hepatitis C\n* Known or suspected myelodysplastic syndrome.\n* Has any medical condition which in the opinion of the Investigator places the patient at an unacceptably high risk for toxicities.",
    "miscellaneous_criteria": ""
}